Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types. Academic Article uri icon

Overview

abstract

  • This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.

publication date

  • December 17, 2021

Research

keywords

  • Diabetes Mellitus, Type 2
  • Drug Costs
  • Insurance, Health
  • Sodium-Glucose Transporter 2 Inhibitors

Identity

PubMed Central ID

  • PMC8796944

Digital Object Identifier (DOI)

  • 10.1001/jamahealthforum.2021.4205

PubMed ID

  • 35977296

Additional Document Info

volume

  • 2

issue

  • 12